Moreover, it is unclear whether an IgE targeting HER2-expressing cancer can drive the stimulation and pro-inflammatory repolarization of key immune effector cells, such as monocytes, or influence immunosuppressive features in the TME. Here, ERBB2 is linked to cancer.